ELV
Bullish signalScored 2026-10-26 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Elevance Health Inc.
- Nom
- Elevance Health Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Healthcare Plans
- Bourse
- NYSE
- Capitalisation
- $96.0B
- Employés
- 96,615
- PDG
- Gail Koziara Boudreaux
- Site web
- https://www.elevancehealth.com
- Marché
- ALHCCICNCCVSHUMMOH
Operating as a major health benefits organization, Elevance Health Inc. commits to guiding consumers, families, and communities across their entire health and wellness path. It facilitates access to vital care, assistance, and tools designed to enable healthier living for approximately 118 million individuals. The company's comprehensive offerings span medical, digital, pharmaceutical, behavioral health, clinical, and other care solutions. Founded in 1944 and based in Indianapolis, Indiana, this entity adopted its current name, Elevance Health Inc., in June 2022, having previously operated as Anthem, Inc.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 3 725 titres (~1 364 517,25 $ US) VENTE TOTALE: 151 titres (~60 667,27 $ US)
- Insiders
- PERU RAMIRO GBOUDREAUX GAILDixon Robert L JR
- Total bought
-
$1,364,517
Avg buy (VWAP, 90d window) —
- Total sold
-
$122,083
Avg sell (VWAP, 90d window) $447.19 vs last close $431.32 (-3.5%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-07-17
- Liquidity
- Liquid $574,819,409/day · 20d vol
- Last synced
-
2026-10-27 09:40:26
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-01-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-09-05 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-08-26 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-08-13 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-08-05 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-07-10 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-06-24 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-05-30 | Gilbert Cisneros | Sale | $1,001 - $15,000 |
| 2025-05-15 | Robert P. Bresnahan | Sale (Full) | $15,001 - $50,000 |
| 2025-05-12 | Jefferson Shreve | Sale (Full) | $15,001 - $50,000 |
| 2025-04-29 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-04-11 | Daniel Milton Newhouse | Sale (Partial) | $1,001 - $15,000 |
| 2025-03-10 | Jared Moskowitz | Sale (Full) | $1,001 - $15,000 |
| 2025-03-10 | Jared Moskowitz | Sale (Full) | $1,001 - $15,000 |
| 2025-02-24 | Jefferson Shreve | Purchase | $15,001 - $50,000 |
| 2025-01-13 | Val Hoyle | Sale (Full) | $1,001 - $15,000 |
| 2025-01-13 | Robert P. Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2025-01-09 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2024-11-19 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2024-11-08 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2024-10-29 | Val Hoyle | Purchase | $1,001 - $15,000 |
| 2024-09-04 | John James | Sale (Full) | $1,001 - $15,000 |
| 2024-07-05 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2024-07-01 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2024-04-10 | Daniel Milton Newhouse | Purchase | $1,001 - $15,000 |
| 2024-03-25 | Michael T. McCaul | Exchange | $100,001 - $250,000 |
| 2024-03-25 | Michael T. McCaul | Sale | $100,001 - $250,000 |
| 2024-03-25 | Michael T. McCaul | Sale | $100,001 - $250,000 |
| 2024-02-20 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2024-02-13 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2024-02-01 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2024-02-01 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2023-12-04 | John R. Curtis | Sale (Full) | $1,001 - $15,000 |
| 2023-11-16 | John James | Purchase | $1,001 - $15,000 |
| 2023-11-10 | John James | Purchase | $1,001 - $15,000 |
| 2023-10-31 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-24 | Greg Stanton | Sale (Full) | $1,001 - $15,000 |
| 2023-10-13 | Michael T. McCaul | Purchase | $50,001 - $100,000 |
| 2023-10-13 | Michael T. McCaul | Purchase | $50,001 - $100,000 |
| 2023-10-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-09-29 | Michael T. McCaul | Purchase | $50,001 - $100,000 |
| 2023-09-29 | Michael T. McCaul | Purchase | $50,001 - $100,000 |
| 2023-09-26 | Greg Stanton | Purchase | $1,001 - $15,000 |
| 2023-09-15 | Michael T. McCaul | Purchase | $50,001 - $100,000 |
| 2023-09-15 | Michael T. McCaul | Purchase | $100,001 - $250,000 |
| 2023-09-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-07-05 | Richard Ray Larsen | Sale (Full) | $1,001 - $15,000 |
| 2023-06-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-19 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-05-10 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2023-05-10 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2023-04-26 | John R. Curtis | Purchase | $1,001 - $15,000 |
| 2023-04-10 | Ro Khanna | Sale | $50,001 - $100,000 |
| 2023-03-24 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-03-14 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-02-14 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-02-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-02-10 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2023-01-11 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-01-06 | Richard Ray Larsen | Purchase | $1,001 - $15,000 |
| 2023-01-03 | Robert J. Wittman | Sale (Partial) | $1,001 - $15,000 |
| 2022-12-20 | John R. Curtis | Sale (Full) | $1,001 - $15,000 |
| 2022-12-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-11-30 | Michael T. McCaul | Sale | $50,001 - $100,000 |
| 2022-11-30 | Michael T. McCaul | Sale | $50,001 - $100,000 |
| 2022-07-01 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2022-07-01 | Michael T. McCaul | Sale | $50,001 - $100,000 |
| 2022-06-16 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-26 | Michael T. McCaul | Sale | $50,001 - $100,000 |
| 2022-05-26 | Michael T. McCaul | Sale | $100,001 - $250,000 |
| 2022-05-20 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2022-05-20 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2022-05-20 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2022-05-06 | Michael T. McCaul | Sale | $100,001 - $250,000 |
| 2022-05-06 | Michael T. McCaul | Sale | $100,001 - $250,000 |
| 2022-01-28 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2021-12-15 | Michael T. McCaul | Sale | $15,001 - $50,000 |
Signal
Bullish signalScored 2026-10-26 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
ELV presents a mixed profile: a solid earnings catalyst (Q3 beat, raised 2026 guidance, net insider buying) is partially offset by deteriorating fundamentals, with shrinking margins, declining ROIC, and reduced…
The first sentence of the analysis written for ELV on 2026-10-26 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Bullish signal
Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Unavailable or mixed. Current ratio 1.24 · operating margin 4.1%
Suggested stop 392.79, nearest stored support minus 0.5 ATR(8.9% under the last close). Reward/risk to the next stored resistance is 0.13. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-26 Implied Volatility Surging for Elevance Health Stock Options Investors need to pay close attention to ELV stock based on the movements in the options market lately.
- 2026-10-25 Elevance Health, Inc. $ELV Stock Sold by Iridian Asset Management LLC CT Iridian Asset Management LLC CT decreased its holdings in Elevance Health, Inc. (NYSE: ELV) by 31.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,252 shares of the company''s stock after selling 4,737 shares during the quarter. Elevance Health comprises
- 2026-10-25 Elevance Health (NYSE:ELV) Stock: Insider Mark Kaye Sells 10,584 Shares Elevance Health, Inc. (NYSE: ELV - Get Free Report) CFO Mark Kaye sold 10,584 shares of the stock in a transaction that occurred on Thursday, October 22nd. The stock was sold at an average price of $440.13, for a total value of $4,658,335.92. Following the completion of the transaction, the chief financial officer directly owned 19,919
- 2026-10-23 ELV vs. RVTY: Which Stock Is the Better Value Option? Investors looking for stocks in the Medical Services sector might want to consider either Elevance Health (ELV) or Revvity (RVTY). But which of these two stocks offers value investors a better bang for their buck right now?
- 2026-10-21 Elevance Health: Better Results, But Not Enough To Buy Elevance Health raised its 2026 adjusted EPS guidance to at least $29, but the sustainability of its earnings recovery remains uncertain. Third-quarter adjusted EPS rose 15.9%, while nine-month operating gain declined 25.7%, highlighting the gap between improving earnings and underlying profitability. Health Benefits margins remain under pressure, particularly in Medicaid, despite improving medical cost trends and stronger quarterly results.
- 2026-10-21 Elevance: 3 Key Takeaways for Long-Term Investors Elevance raised its 2026 earnings baseline to at least $26.75 per share. Carelon''s cancer program reduced avoidable inpatient admissions by 15%.
- 2026-10-21 2 Healthcare Stocks to Buy After Crushing Q3 Earnings Expectations: ELV & ISRG Intuitive Surgical (ISRG) and Elevance Health (ELV) delivered impressive Q3 earnings beats, making both healthcare stocks worth considering as their growth outlooks improve.
- 2026-10-21 Elevance Health, Inc. (ELV) Hits Fresh High: Is There Still Room to Run? Elevance Health (ELV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company''s fundamentals for clues.
- 2026-10-21 Elevance Health, Inc. (ELV) Q3 2026 Earnings Call Transcript Elevance Health, Inc. (ELV) Q3 2026 Earnings Call Transcript
- 2026-10-21 ELV Beats Q3 Earnings Estimates on Carelon Strength, Raises 2026 Outlook Elevance Health beats Q3 EPS estimate by 50% as Carelon grows despite declining medical membership, and lifts its 2026 underlying earnings baseline to $26.75.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 25.6% | 27.9% | 27.4% | 25.5% | 26.0% | |
| Ebit Margin | 4.1% | 5.1% | 5.1% | 5.4% | 6.3% | |
| Ebitda Margin | 4.9% | 5.9% | 6.1% | 6.5% | 7.2% | |
| Operating Profit Margin | 4.1% | 5.0% | 5.1% | 5.4% | 6.5% | |
| Pretax Profit Margin | 3.4% | 4.5% | 4.5% | 4.9% | 5.7% | |
| Continuous Operations Profit Margin | 2.8% | 3.4% | 3.5% | 3.8% | 4.4% | |
| Net Profit Margin | 2.8% | 3.4% | 3.5% | 3.8% | 4.4% | |
| Bottom Line Profit Margin | 2.8% | 3.4% | 3.5% | 3.8% | 4.4% | |
| Current Ratio | 1.239 | 1.099 | 0.971 | 1.026 | 0.939 | |
| Quick Ratio | 1.239 | 1.099 | 0.971 | 1.026 | 0.939 | |
| Solvency Ratio | 0.093 | 0.098 | 0.111 | 0.114 | 0.121 | |
| Cash Ratio | 0.476 | 0.427 | 0.334 | 0.396 | 0.314 | |
| Price To Earnings Ratio | 13.922 | 14.293 | 18.580 | 20.886 | 18.358 | |
| Price To Earnings Growth Ratio | -5.704 | 8.436 | 5.565 | -7.643 | 0.477 | |
| Forward Price To Earnings Growth Ratio | -5.704 | 8.436 | 5.565 | -7.643 | 0.477 | |
| Price To Earnings Diluted Ratio | 13.955 | 14.365 | 18.698 | 21.127 | 18.744 | |
| Price To Earnings Diluted Growth Ratio | -6.399 | 7.876 | 4.830 | -11.611 | 0.499 | |
| Price To Book Ratio | 1.772 | 2.079 | 2.796 | 3.397 | 3.134 | |
| Price To Sales Ratio | 0.390 | 0.486 | 0.641 | 0.786 | 0.815 | |
| Price To Free Cash Flow Ratio | 24.497 | 18.872 | 16.246 | 16.988 | 15.530 | |
| Price To Operating Cash Flow Ratio | 18.124 | 14.791 | 13.634 | 14.658 | 13.512 | |
| Debt To Assets Ratio | 0.274 | 0.280 | 0.245 | 0.251 | 0.255 | |
| Debt To Equity Ratio | 0.757 | 0.792 | 0.678 | 0.712 | 0.690 | |
| Debt To Capital Ratio | 0.431 | 0.442 | 0.404 | 0.416 | 0.408 | |
| Long Term Debt To Capital Ratio | 0.417 | 0.420 | 0.378 | 0.389 | 0.379 | |
| Financial Leverage Ratio | 2.769 | 2.829 | 2.771 | 2.835 | 2.703 | |
| Working Capital Turnover Ratio | 59.520 | 260.590 | -3,984.651 | -659.347 | 371.686 | |
| Operating Cash Flow Ratio | 0.215 | 0.299 | 0.412 | 0.450 | 0.539 | |
| Operating Cash Flow Sales Ratio | 0.022 | 0.033 | 0.047 | 0.054 | 0.060 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.740 | 0.784 | 0.839 | 0.863 | 0.870 | |
| Debt Service Coverage Ratio | 3.095 | 2.550 | 2.857 | 3.008 | 2.922 | |
| Interest Coverage Ratio | 5.786 | 7.500 | 8.490 | 9.931 | 11.211 | |
| Short Term Operating Cash Flow Coverage Ratio | 3.109 | 2.680 | 3.955 | 4.316 | 4.167 | |
| Operating Cash Flow Coverage Ratio | 0.129 | 0.178 | 0.302 | 0.326 | 0.336 | |
| Capital Expenditure Coverage Ratio | 3.844 | 4.624 | 6.220 | 7.291 | 7.695 | |
| Dividend Paid And Capex Coverage Ratio | 1.622 | 2.101 | 2.996 | 3.528 | 3.817 | |
| Dividend Payout Ratio | 0.270 | 0.252 | 0.233 | 0.209 | 0.181 | |
| Enterprise Value Multiple | 10.509 | 10.524 | 12.396 | 13.976 | 13.269 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 25.6% | ▼-2.3% | ▼-0.9% |
| Ebit Margin | 4.1% | ▼-1.1% | ▼-1.1% |
| Ebitda Margin | 4.9% | ▼-1.1% | ▼-1.3% |
| Operating Profit Margin | 4.1% | ▼-0.9% | ▼-1.1% |
| Pretax Profit Margin | 3.4% | ▼-1.1% | ▼-1.2% |
| Continuous Operations Profit Margin | 2.8% | ▼-0.5% | ▼-0.7% |
| Net Profit Margin | 2.8% | ▼-0.5% | ▼-0.7% |
| Bottom Line Profit Margin | 2.8% | ▼-0.5% | ▼-0.7% |
| Current Ratio | 1.239 | ▲0.140 | ▲0.184 |
| Quick Ratio | 1.239 | ▲0.140 | ▲0.184 |
| Solvency Ratio | 0.093 | ▼-0.005 | ▼-0.014 |
| Cash Ratio | 0.476 | ▲0.049 | ▲0.086 |
| Price To Earnings Ratio | 13.922 | ▼-0.371 | ▼-3.286 |
| Price To Earnings Growth Ratio | -5.704 | ▼-14.140 | ▼-5.930 |
| Forward Price To Earnings Growth Ratio | -5.704 | ▼-14.140 | ▼-5.930 |
| Price To Earnings Diluted Ratio | 13.955 | ▼-0.410 | ▼-3.423 |
| Price To Earnings Diluted Growth Ratio | -6.399 | ▼-14.275 | ▼-5.438 |
| Price To Book Ratio | 1.772 | ▼-0.307 | ▼-0.864 |
| Price To Sales Ratio | 0.391 | ▼-0.095 | ▼-0.233 |
| Price To Free Cash Flow Ratio | 24.497 | ▲5.625 | ▲6.070 |
| Price To Operating Cash Flow Ratio | 18.124 | ▲3.333 | ▲3.180 |
| Debt To Assets Ratio | 0.274 | ▼-0.006 | ▲0.013 |
| Debt To Equity Ratio | 0.757 | ▼-0.034 | ▲0.032 |
| Debt To Capital Ratio | 0.431 | ▼-0.011 | ▲0.011 |
| Long Term Debt To Capital Ratio | 0.416 | ▼-0.003 | ▲0.020 |
| Financial Leverage Ratio | 2.769 | ▼-0.061 | ▼-0.013 |
| Working Capital Turnover Ratio | 59.520 | ▼-201.069 | ▲849.961 |
| Operating Cash Flow Ratio | 0.215 | ▼-0.084 | ▼-0.168 |
| Operating Cash Flow Sales Ratio | 0.021 | ▼-0.011 | ▼-0.021 |
| Free Cash Flow Operating Cash Flow Ratio | 0.740 | ▼-0.044 | ▼-0.079 |
| Debt Service Coverage Ratio | 3.095 | ▲0.544 | ▲0.208 |
| Interest Coverage Ratio | 5.786 | ▼-1.714 | ▼-2.798 |
| Short Term Operating Cash Flow Coverage Ratio | 3.109 | ▲0.428 | ▼-0.537 |
| Operating Cash Flow Coverage Ratio | 0.129 | ▼-0.049 | ▼-0.125 |
| Capital Expenditure Coverage Ratio | 3.844 | ▼-0.780 | ▼-2.091 |
| Dividend Paid And Capex Coverage Ratio | 1.622 | ▼-0.479 | ▼-1.191 |
| Dividend Payout Ratio | 0.270 | ▲0.018 | ▲0.041 |
| Enterprise Value Multiple | 10.509 | ▼-0.015 | ▼-1.626 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $77.75B | $85.90B | $109.91B | $123.11B | $113.01B | |
| Enterprise value | $101.50B | $110.32B | $130.03B | $141.52B | $133.02B | |
| EV / Sales | 0.51x | 0.62x | 0.76x | 0.90x | 0.96x | |
| EV / Op. cash flow | 23.66x | 18.99x | 16.13x | 16.85x | 15.90x | |
| EV / Free cash flow | 31.98x | 24.23x | 19.22x | 19.53x | 18.28x | |
| EV / EBITDA | 10.51x | 10.52x | 12.40x | 13.98x | 13.27x | |
| Net debt / EBITDA | 2.46x | 2.33x | 1.92x | 1.82x | 2.00x | |
| Current ratio | 1.24x | 1.10x | 0.97x | 1.03x | 0.94x | |
| Income quality | 0.76x | 0.97x | 1.35x | 1.40x | 1.37x | |
| Graham number | $337 | $320 | $312 | $289 | $289 | |
| Graham net-net | -$255 | -$246 | -$230 | -$209 | -$202 | |
| Tax burden | 84.4% | 75.7% | 77.6% | 77.6% | 77.0% | |
| Interest burden | 82.7% | 87.0% | 88.2% | 89.9% | 90.9% | |
| Working capital | $4.77B | $1.92B | -$565.0M | $479.0M | -$954.0M | |
| Invested capital | $49.44B | $47.51B | $39.97B | $40.10B | $38.44B | |
| Return on assets | 4.7% | 5.1% | 5.5% | 5.7% | 6.3% | |
| Operating ROA | 6.8% | 7.9% | 8.3% | 8.4% | 9.6% | |
| Return on tangible assets | 6.9% | 7.8% | 8.2% | 8.7% | 9.7% | |
| Return on equity | 12.9% | 14.5% | 15.2% | 16.3% | 16.9% | |
| Return on invested capital | 6.6% | 6.7% | 7.4% | 7.6% | 8.2% | |
| Return on capital employed | 8.0% | 9.1% | 9.8% | 10.0% | 10.9% | |
| Earnings yield | 7.3% | 7.0% | 5.4% | 4.8% | 5.4% | |
| Free cash flow yield | 4.1% | 5.3% | 6.2% | 5.9% | 6.4% | |
| Capex / Op. cash flow | 26.0% | 21.6% | 16.1% | 13.7% | 13.0% | |
| Capex / Depreciation | 72.2% | 90.2% | 74.3% | 68.8% | 83.5% | |
| Capex / Sales | 0.6% | 0.7% | 0.8% | 0.7% | 0.8% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.1% | 0.1% | 0.2% | 0.2% | 0.2% | |
| Intangibles / Total assets | 32.5% | 34.5% | 32.7% | 33.8% | 35.8% | |
| Days sales outstanding | 28d | 27d | 27d | 27d | 26d | |
| Days payables outstanding | 42d | 45d | 47d | 49d | 48d | |
| Operating cycle | 28d | 27d | 27d | 27d | 26d | |
| Cash conversion cycle | -14d | -18d | -21d | -21d | -23d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-9.5%EV / Sales ▼-18.3%EV / EBITDA ▼-0.1%EV / Op. cash flow ▲+4.665Earnings yield ▲+0.003Graham number ▲+16.923
Profitability
Return on equity ▼-0.016Return on assets ▼-0.005Return on invested capital ▼-0.001Return on capital employed ▼-0.011Operating ROA ▼-0.011Income quality ▼-0.215Tax burden ▲+0.087
Efficiency
Days sales outstanding ▲+0.976Days payables outstanding ▼-2.984Operating cycle ▲+0.976Cash conversion cycle ▲+3.959Capex / Sales ▼-0.001R&D / Sales n/a
Balance-sheet strength
Current ratio ▲+0.140Net debt / EBITDA ▲+0.129Working capital ▲+2847000000.000Invested capital ▲+1932000000.000Intangibles / Total assets ▼-0.020
Change over 5 years
Valuation
Market cap ▼-31.2%EV / Sales ▼-46.9%EV / EBITDA ▼-20.8%EV / Op. cash flow ▲+7.755Earnings yield ▲+0.019Graham number ▲+48.445
Profitability
Return on equity ▼-0.040Return on assets ▼-0.016Return on invested capital ▼-0.015Return on capital employed ▼-0.029Operating ROA ▼-0.028Income quality ▼-0.614Tax burden ▲+0.074
Efficiency
Days sales outstanding ▲+2.412Days payables outstanding ▼-6.000Operating cycle ▲+2.412Cash conversion cycle ▲+8.412Capex / Sales ▼-0.002R&D / Sales n/a
Balance-sheet strength
Current ratio ▲+0.300Net debt / EBITDA ▲+0.462Working capital ▲+5723000000.000Invested capital ▲+11008000000.000Intangibles / Total assets ▼-0.032